With Sanofi/Genzyme Corp.’s Aubagio (teriflunomide) obtaining FDA approval Sept. 12 for patients with relapsing forms of multiple sclerosis, Wall Street’s initial take was that currently stalled Lemtrada (alemtuzumab) represented the company’s bigger opportunity in the space.
Analyst Mark Clark of Deutsche Bank AGpredicted that Aubagio sales would reach about $273 million in 2016, while broader consensus...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?